Chronic myelomonocytic leukemia in the light of the WHO proposals.
Haematologica
; 92(7): 974-7, 2007 Jul.
Article
em En
| MEDLINE
| ID: mdl-17606449
ABSTRACT
The WHO classification moved CMML to myeloproliferative/myelodysplastic disorders, and defined CMML I and CMML II according to medullary and peripheral blast count. To confirm these proposals, we analyzed 266 patients with CMML I and 73 patients with CMML II. Median survival time was 20 months for CMML I, and 15 months for CMML II (p<0.005). The cumulative risk of AML evolution differed between patient groups (p=0,001). No conclusive differences in clinical, morphologic, hematologic or cytogenetic parameters were found. These data support the WHO proposals for the classifi-cation of CMML.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Organização Mundial da Saúde
/
Leucemia Mielomonocítica Crônica
Limite:
Humans
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article